Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Decrease in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 10,900 shares, a decrease of 14.8% from the December 31st total of 12,800 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average daily volume of 28,500 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a research note on Wednesday, January 15th.

Aprea Therapeutics Trading Up 2.9 %

Shares of APRE traded up $0.11 during trading hours on Friday, reaching $3.91. 13,587 shares of the company traded hands, compared to its average volume of 34,076. The firm has a market cap of $21.23 million, a price-to-earnings ratio of -1.39 and a beta of 0.75. Aprea Therapeutics has a 12-month low of $2.15 and a 12-month high of $8.85. The stock’s fifty day moving average price is $3.50 and its 200 day moving average price is $3.46.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.11. The business had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.45 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. On average, research analysts forecast that Aprea Therapeutics will post -2.55 earnings per share for the current year.

Hedge Funds Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics at the end of the most recent reporting period. Institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.